eIF4B和eIF5A在甲状腺乳头状癌中的表达及二者体外对甲状腺癌细胞增殖的影响  

Expressions of eukaryotic initiation factor-4B and eukaryotic initiation factor-5A in papillary thyroid carcinoma and their effects on cell proliferation in vitro

作　　者：刘静 栾中华 张琳刚 周迎 Liu Jing;Luan Zhonghua;Zhang Lingang;Zhou Ying(Department of Pathology,Yuncheng Central Hospital,Yuncheng 044000,China;Department of Emergency,Yuncheng Central Hospital,Yuncheng 044000,China)

机构地区：[1]运城市中心医院病理科,运城044000 [2]运城市中心医院急诊科,运城044000

出　　处：《肿瘤研究与临床》2023年第8期578-583,共6页Cancer Research and Clinic

基　　金：运城市中心医院院级课题(YJ2022017)。

摘　　要：目的探讨甲状腺乳头状癌组织真核细胞起始因子4B(eIF4B)和真核细胞起始因子5A(eIF5A)的表达及二者体外对细胞增殖的调控作用。方法回顾性分析2020年1月至2021年10月在运城市中心医院行手术根治的61例甲状腺乳头状癌患者的临床资料。均取术后留存的肿瘤组织和距肿瘤边缘>1 cm的癌旁正常甲状腺组织,应用免疫组织化学法检测各组织eIF4B、eIF5A及增殖细胞核抗原(PCNA)的表达,分析eIF4B、eIF5A表达与患者临床病理特征的关系及eIF4B、eIF5A、PCNA三者间关系。选择甲状腺癌细胞株SW1736、正常甲状腺细胞株HT-ori3,应用实时荧光定量聚合酶链反应(qRT-PCR)检测eIF4B、eIF5A mRNA的表达。分别合成eIF4B、eIF5A的小干扰RNA(siRNA),构建干扰质粒,并转染SW1736细胞,分别为siRNA-eIF4B组、siRNA-eIF5A组,另建立空载质粒转染组和未经转染干预的空白对照组;应用CCK-8法检测细胞增殖活性,应用qRT-PCR法检测PCNA mRNA的表达。结果甲状腺乳头状癌组织中eIF4B、eIF5A阳性率均高于癌旁正常甲状腺组织[65.57%(40/61)比29.51%(18/61),57.38%(35/61)比9.84%(6/61),均P<0.001];不同肿瘤长径[>3 cm比≤3 cm:88.89%(16/18)比55.81%(24/43),77.78%(14/18)比48.84%(21/43),均P<0.05]、有无淋巴结转移[有比无:85.00%(17/20)比56.10%(23/41),80.00%(16/20)比46.34%(19/41),均P<0.05]和不同结节数[多个比单个:86.67%(13/15)比58.70%(27/46),86.67%(13/15)比47.83%(22/46),均P<0.05]患者eIF4B和eIF5A阳性率差异均有统计学意义,不同年龄、性别患者间eIF4B和eIF5A阳性率差异均无统计学意义(均P>0.05)。甲状腺乳头状癌中eIF4B评分和PCNA阳性细胞比例(r=0.66,P=0.032)、eIF5A评分和PCNA阳性细胞比例(r=0.62,P=0.024)、eIF4B评分和eIF5A评分(r=0.63,P=0.021)均具有正相关性。甲状腺癌SW1736细胞中eIF4B mRNA、eIF5A mRNA的表达量均高于正常甲状腺HT-ori3细胞(均P<0.05)。siRNA-eIF4B组、siRNA-eIF5A组SW1736细胞增殖活性、PCNA mRNA的表达量均Objective To investigate the expressions of eukaryotic initiation factor-4B(eIF4B)and eukaryotic initiation factor-5A(eIF5A)in papillary thyroid carcinoma tissues,and to analyze their regulatory effects on cell proliferation in vitro.Methods The clinical data of 61 patients diagnosed with papillary thyroid carcinoma who received surgical resection at Yuncheng Central Hospital from January 2020 to October 2021 were retrospectively analyzed.The postoperative tumor tissues and paracancerous normal thyroid tissues(>1 cm from the margin of the mass)were retained.Immunohistochemistry was used to detect the expressions of eIF4B,eIF5A and proliferating cell nuclear antigen(PCNA)in different tissues.The correlation of eIF4B,eIF5A expressions with the clinicopathological characteristics of patients,and the relationship between eIF4B,eIF5A and PCNA were analyzed.The thyroid cancer cell line SW1736 and normal thyroid cell line HT-ori3 were selected.The expressions of eIF4B mRNA and eIF5A mRNA were detected by using real-ime quantitative polymerase chain reaction(qRT-PCR).After the small interfering RNA(siRNA)of siRNA-eIF4B and siRNA-eIF5A were synthesized,the interfering plasmids were constructed,and SW1736 cells were transfected,siRNA-eIF4B group and siRNA-eIF5A group were obtained;the empty plasmid transfection group and the blank control group without transfection intervention were established.The cell proliferation activity was detected by using CCK-8 assay,and the expression of PCNA mRNA was detected by using qRT-PCR.Results The positive rates of eIF4B and eIF5A in papillary thyroid cancer tissues were higher than those in paracancerous normal thyroid tissues[65.57%(40/61)vs.29.51%(18/61),57.38%(35/61)vs.9.84%(6/61),P<0.001].The positive rates of eIF4B and eIF5A were statistically different in patients with different tumor diameter[>3 cm vs.≤3 cm:88.89%(16/18)vs.55.81%(24/43),77.78%(14/18)vs.48.84%(21/43),all P<0.05],lymph node metastasis[with vs.without:85.00%(17/20)vs.56.10%(23/41),80.00%(16/20)vs.46.34%(19/41),all

关 键 词：甲状腺肿瘤 真核细胞起始因子4B 真核细胞起始因子5A 细胞增殖 

分 类 号：R736.1[医药卫生—肿瘤]